Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT: Dapagliflozin for Prevention of Chemotherapy-Induced Cardiotoxicity in Breast Cancer
NCT06341842Phase 2Recruiting
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Oct 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in cancer therapy-related cardiac dysfunction (CTRCD), sponsored by IRCCS San Matteo Foundation. Started Oct 2023; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
cancer therapy-related cardiac dysfunction (CTRCD)
Beyond the preview
Go deeper on NCT06341842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06341842.